Excellence in 
Biotech Investments

THE ACCESS TO FAST GROWING BIOTECHNOLOGY COMPANIES
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 25 years of experience. The shares of BB Biotech are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and the Stock Exchange in Milan. Its investments are focused on listed companies that are developing and commercializing novel drugs that offer sound value for the healthcare system.

Corporate News January 21, 2022

2021 was a difficult year for biotech equity markets – increased dividend of CHF 3.85 proposed

The year 2021 was a volatile market environment for all involved in biotechnology investing, including BB Biotech. The biotech and pharmaceutical sector adapted to the SARS-CoV-2 virus pandemic cycling through Delta and now Omicron variants with offers of booster vaccines, therapeutic antibodies and most recently new antiviral drugs. For human health overall, new modalities such as genetic medicines, cell-based therapies and RNA-based drugs continue to make positive strides and are expected to improve the prognosis of severe and chronic diseases in the coming years. 

  • Portfolio & Strategy

    Expert Portfolio

    BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential. 

  • Insights

    Top Know-How

    A team of proven biotech specialists at Bellevue Asset Management AG with a successful track record takes care of investments in the most attractive biotech companies. In this section you will get a comprehensive insight into the biotech sector and relevant investment topics.

  • ESG

    Sustainability

    Each investment is systematically reviewed for sustainability risks and breaches of elementary human rights. Bellevue Asset Management AG is a signatory of UN Principles for Responsible Investment.

  • Investment strategy

    Active Management with High Conviction

    Besides profitable large cap companies, BB Biotech is building up its investments in promising small and mid cap companies. The team of investment experts is concentrating not only on established target areas such as oncology, orphan diseases and neurological indications, but also on the technologies of tomorrow that could lead to novel treatment methods with attractive therapeutic profiles and substantial economic rewards.

  • Geschäftskollegen im Austausch